Table 3.

Total exposure to study medication

	Placebo	CZP 200 mg Q2W	CZP 400 mg Q2W
Week 16	46·9 PY	106·5 PY	104·5 PY
Week 48	–	310·8 PY	418·0 PY
Week 96	–	771·7 PY	699·6 PY
Week 144	–	1211·4 PY	1019·9 PY

CZP, certolizumab pegol; Q2W, every 2 weeks; PY, patient‐years.